Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VINOD PULLARKAT

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1164433645
CMS profile
325119
Location
DUARTE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$105,031.62

104 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Alexion Pharmaceuticals, Inc. $30,874.47 18
JAZZ PHARMACEUTICALS INC. $19,437.80 20
GENZYME CORPORATION $15,284.46 7
Novartis Pharmaceuticals Corporation $11,624.51 22
Rigel Pharmaceuticals, Inc. $11,538.18 13
SOBI, INC $4,743.57 2
SERVIER PHARMACEUTICALS LLC $4,307.49 4
ABBVIE INC. $3,628.22 4
Pharmacosmos Therapeutics Inc. $2,943.48 3
PFIZER INC. $218.80 2
Astellas Pharma US Inc $153.98 1
Incyte Corporation $123.87 2
Daiichi Sankyo Inc. $56.77 2
Merck Sharp & Dohme LLC $44.25 2
Celgene Corporation $27.12 1
Amgen Inc. $24.65 1

Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VINOD PULLARKAT

NPI 1164433645 · CMS profile ID 325119

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

DUARTE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164433645?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VINOD PULLARKAT, NPI 1164433645, CMS profile ID 325119. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164433645?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). VINOD PULLARKAT, NPI 1164433645, CMS profile ID 325119. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164433645?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
VINOD PULLARKAT, NPI 1164433645, CMS profile ID 325119, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1164433645?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

104 matching records · $105,031.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 104 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 104.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $24.6505/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116031644 CMS
Rigel Pharmaceuticals, Inc. $4,384.0005/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145201568 CMS
GENZYME CORPORATION $49.1605/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139974045 CMS
JAZZ PHARMACEUTICALS INC. $2.6905/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202316 CMS
JAZZ PHARMACEUTICALS INC. $107.1105/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202318 CMS
JAZZ PHARMACEUTICALS INC. $77.5005/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202304 CMS
JAZZ PHARMACEUTICALS INC. $48.0005/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202306 CMS
JAZZ PHARMACEUTICALS INC. $8,580.0005/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202336 CMS
Rigel Pharmaceuticals, Inc. $120.2005/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145199399 CMS
JAZZ PHARMACEUTICALS INC. $179.2505/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202308 CMS
JAZZ PHARMACEUTICALS INC. $149.9905/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202334 CMS
ABBVIE INC. $1,800.0005/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105324567 CMS
ABBVIE INC. $900.0005/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105324571 CMS
Novartis Pharmaceuticals Corporation $30.1605/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156561 CMS
JAZZ PHARMACEUTICALS INC. $536.2004/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202312 CMS
Novartis Pharmaceuticals Corporation $24.1504/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156537 CMS
SOBI, INC $4,625.0004/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141408746 CMS
SOBI, INC $118.5704/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141441480 CMS
Celgene Corporation $27.1204/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101196807 CMS
JAZZ PHARMACEUTICALS INC. $19.4504/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202322 CMS
Rigel Pharmaceuticals, Inc. $3.7604/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145199397 CMS
Incyte Corporation $24.8704/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141300485 CMS
Novartis Pharmaceuticals Corporation $18.1304/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156527 CMS
Rigel Pharmaceuticals, Inc. $8.2304/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145201566 CMS
JAZZ PHARMACEUTICALS INC. $25.2804/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202342 CMS
JAZZ PHARMACEUTICALS INC. $18.0403/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202330 CMS
Rigel Pharmaceuticals, Inc. $68.3503/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145207323 CMS
Rigel Pharmaceuticals, Inc. $39.9303/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145207325 CMS
Merck Sharp & Dohme LLC $22.1803/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141828326 CMS
Novartis Pharmaceuticals Corporation $31.2103/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156525 CMS
Rigel Pharmaceuticals, Inc. $5,480.0003/07/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145203353 CMS
Novartis Pharmaceuticals Corporation $117.2203/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156517 CMS
Alexion Pharmaceuticals, Inc. $54.8003/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093884012 CMS
Alexion Pharmaceuticals, Inc. $1,446.2003/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093895219 CMS
Alexion Pharmaceuticals, Inc. $176.3703/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093958579 CMS
Alexion Pharmaceuticals, Inc. $74.7303/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094021993 CMS
Alexion Pharmaceuticals, Inc. $371.7703/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094041357 CMS
Alexion Pharmaceuticals, Inc. $14,430.0002/29/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093885464 CMS
GENZYME CORPORATION $135.4002/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139974041 CMS
GENZYME CORPORATION $3,324.0002/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139974043 CMS
Rigel Pharmaceuticals, Inc. $613.2002/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145207347 CMS
Rigel Pharmaceuticals, Inc. $258.2302/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145207349 CMS
Rigel Pharmaceuticals, Inc. $350.0002/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145207355 CMS
Rigel Pharmaceuticals, Inc. $50.0002/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145207357 CMS
Rigel Pharmaceuticals, Inc. $50.0002/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145207367 CMS
Rigel Pharmaceuticals, Inc. $112.2802/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145207369 CMS
Novartis Pharmaceuticals Corporation $1,350.0001/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156511 CMS
Novartis Pharmaceuticals Corporation $2,513.0001/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156519 CMS
Novartis Pharmaceuticals Corporation $54.8601/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156521 CMS
Novartis Pharmaceuticals Corporation $621.6401/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087156523 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $88,778.44 103
PY2020 $43,915.57 38
PY2021 $84,658.55 67
PY2022 $85,754.23 80
PY2023 $75,850.95 79
PY2024 $105,031.62 104
PY2025 $91,701.24 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,113.56 6
PY2025 Principal investigator $967,606.16 60
PY2024 Recipient $967.51 2
PY2024 Principal investigator $2,803,727.07 103
PY2023 Recipient $2,331.71 2
PY2023 Principal investigator $600,439.93 47
PY2022 Recipient $62.18 3
PY2022 Principal investigator $1,467,750.47 41
PY2021 Recipient $825.00 1
PY2021 Principal investigator $1,179,593.01 34
PY2020 Recipient $1,650.00 1
PY2020 Principal investigator $1,412,692.49 56
PY2019 Principal investigator $959,685.14 38

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,750.00 12/31/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination with Ruxolitinib in Myeloproliferative Neoplasm Subjects No dispute reported 06/30/2026 1202409085
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,107.93 12/17/2025 Non-covered Recipient Entity
CITY OF HOPE MEDICAL CENTER
A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Have Hb10 g/dL in Response to Anti-C5 Antibody and Switch to Iptacopan No dispute reported 06/30/2026 1190301265
Principal investigator 1 ABBVIE INC. $840.84 12/04/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408987
Principal investigator 1 GENZYME CORPORATION $30,300.00 11/24/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3, multicenter, randomized, double-bline, placebo controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (WAIHA) No dispute reported 06/30/2026 1226084572
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,288.74 11/24/2025 Non-covered Recipient Entity
CITY OF HOPE MEDICAL CENTER
A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome No dispute reported 06/30/2026 1190301267
Principal investigator 1 ABBVIE INC. $232.70 11/04/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408938
Recipient Novartis Pharma AG $677.66 10/30/2025 Covered Recipient Physician CLNP023C12303 No dispute reported 06/30/2026 1248109637
Recipient Novartis Pharmaceuticals Corporation $393.00 10/20/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291395
Principal investigator 1 Servier BioInnovation $2,481.45 10/10/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964926
Principal investigator 1 ABBVIE INC. $458.90 10/09/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408916
Principal investigator 1 Servier BioInnovation $4,917.08 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964892
Principal investigator 1 Servier BioInnovation $10,000.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964894
Principal investigator 1 Servier BioInnovation $1,744.60 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964896
Principal investigator 1 Servier BioInnovation $26,522.82 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964898
Principal investigator 1 Servier BioInnovation $13,429.56 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964900
Principal investigator 1 Servier BioInnovation $8,000.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964902
Principal investigator 1 Servier BioInnovation $14,693.25 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964904
Principal investigator 1 Servier BioInnovation $3,187.07 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964906
Principal investigator 1 Servier BioInnovation $1,750.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964908
Principal investigator 1 Servier BioInnovation $8,840.94 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964910
Principal investigator 1 Servier BioInnovation $4,476.52 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964912
Principal investigator 1 Servier BioInnovation $3,200.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964914
Principal investigator 1 Servier BioInnovation $325.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964916
Principal investigator 1 Servier BioInnovation $750.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964918
Principal investigator 1 Servier BioInnovation $3,750.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964920
Principal investigator 1 Servier BioInnovation $3,900.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964922
Principal investigator 1 Servier BioInnovation $1,000.00 10/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964924
Principal investigator 1 ABBVIE INC. $879.84 09/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408827
Principal investigator 1 ABBVIE INC. $65.00 09/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408831
Principal investigator 1 ABBVIE INC. $16,768.70 09/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408835
Recipient Novartis Pharmaceuticals Corporation $364.70 08/05/2025 Covered Recipient Physician CLNP023C12303 No dispute reported 06/30/2026 1190292127
Recipient SERVIER PHARMACEUTICALS LLC $103.59 07/24/2025 Covered Recipient Physician Phase 1/2 Study of S227928, an Anti-CD74 Antibody-Drug Conjugate (ADC) Targeting MCL-1, as a Single Agent and Combined with Venetoclax (Ven) in Patients with Relapsed/Refractory AML, MDS/AML, or CMML No dispute reported 06/30/2026 1235964854
Principal investigator 1 ABBVIE INC. $1,407.64 07/02/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408643
Principal investigator 1 ABBVIE INC. $97,398.55 07/02/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 1202408646
Principal investigator 1 ABBVIE INC. $390.00 07/02/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408651
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,853.56 06/24/2025 Non-covered Recipient Entity
CITY OF HOPE NATIONAL MEDICAL CENTER ATTN KAREN KELSEY
An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Ipta No dispute reported 06/30/2026 1190300549
Recipient Novartis Pharma AG $359.20 06/13/2025 Covered Recipient Physician CLNP023C12303 No dispute reported 06/30/2026 1248109639
Recipient Novartis Pharmaceuticals Corporation $1,215.41 06/13/2025 Covered Recipient Physician CLNP023C12303 No dispute reported 06/30/2026 1190292132
Principal investigator 1 ABBVIE INC. $131.30 06/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408542
Principal investigator 1 ABBVIE INC. $370.50 06/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408545
Principal investigator 1 ABBVIE INC. $1,341.34 05/06/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408304
Principal investigator 1 Servier BioInnovation $253.50 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964868
Principal investigator 1 Servier BioInnovation $832.98 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964870
Principal investigator 1 Servier BioInnovation $253.50 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964872
Principal investigator 1 Servier BioInnovation $381.88 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964874
Principal investigator 1 Servier BioInnovation $253.50 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964876
Principal investigator 1 Servier BioInnovation $169.00 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964878
Principal investigator 1 Servier BioInnovation $796.25 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964880
Principal investigator 1 Servier BioInnovation $253.50 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964882
Principal investigator 1 Servier BioInnovation $169.00 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964884
Principal investigator 1 Servier BioInnovation $550.88 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964886
Principal investigator 1 Servier BioInnovation $4,897.75 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964888
Principal investigator 1 Servier BioInnovation $550.88 04/23/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964890
Principal investigator 1 ABBVIE INC. $566.80 04/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408174
Principal investigator 1 ABBVIE INC. $709.54 04/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408178
Principal investigator 1 ABBVIE INC. $2,000.00 04/03/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm No dispute reported 06/30/2026 1202408182
Principal investigator 1 SOBI, INC $30,000.00 04/02/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
Real-world treatment patterns and outcomes in patients with immune thrombocytopenic purpura treated with Avatrombopag in the United States No dispute reported 06/30/2026 1240177431
Principal investigator 1 Servier BioInnovation $253.50 03/19/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964860
Principal investigator 1 Servier BioInnovation $253.50 03/19/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964862
Principal investigator 1 Servier BioInnovation $253.50 03/19/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964864
Principal investigator 1 Servier BioInnovation $253.50 03/19/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
CALASPARGASE PEGOL IN ADULTS WITH ALL No dispute reported 06/30/2026 1235964866
Principal investigator 1 ABBVIE INC. $905.84 03/06/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408122
Principal investigator 1 ABBVIE INC. $651.04 02/05/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408077
Principal investigator 1 ABBVIE INC. $1,617.98 02/05/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202408080
Principal investigator 1 Novartis Pharmaceuticals Corporation $632,903.71 01/14/2025 Non-covered Recipient Entity
CITY OF HOPE HISTOCOMPATIBILITY LABORATORY
An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Ipta No dispute reported 06/30/2026 1190305475
Principal investigator 1 ABBVIE INC. $1,320.80 01/02/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1202407939